Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/2/2019
SIETES contiene 92669 citas

 
 
 1 a 20 de 837 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Wallach JD, Eqilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. BMJ 2018;361:24 de mayo. [Ref.ID 102886]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J, Groeneveld PW. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016. JAMA Intern Med 2018;178:julio. [Ref.ID 102882]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Pacurariu A, Plueschke K, Olmo CA, Kurz X. Imposed registries within the European postmarketing surveillance system: Extended analysis and lessons learned for regulators. Pharmacoepidemiol Drug Saf 2018;27:julio. [Ref.ID 102879]
4.Enlace a cita original Cita con resumen
Howard R, Fry B, Gunaseelan V, Lee J, Waljee J, Brummett C, Campbell Jr D, Seese E, Englesbe M, Vu J. Association of opioid prescribing with opioid consumption after surgery in Michigan. JAMA Surgery 2018:7 de noviembre. [Ref.ID 102846]
6.Enlace a cita original Cita con resumen
Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer. A randomized clinical trial. JAMA 2018;319:10 de julio. [Ref.ID 102791]
7.Tiene citas relacionadas Cita con resumen
Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Baah JO, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li P-Z, Hill PC, Schwartzman K, Benedetti A, Menzies D. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med 2018;379:2 de agosto. [Ref.ID 102756]
8.Tiene citas relacionadas Cita con resumen
Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Baah JO, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata KE, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion-M-J, Li P-Z, Schwartzman K, Benedetti A. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 2018;379:2 de agosto. [Ref.ID 102755]
9.Enlace a cita originalTiene citas relacionadas Cita con resumen
Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K, on behalf of the show SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018;391:9 de junio. [Ref.ID 102692]
10.Enlace a cita originalTiene citas relacionadas Cita con resumen
Blankestijn PJ, Bots ML. Renal denervation in uncontrolled hypertension: the story continues to unfold. Lancet 2018;391:9 de junio. [Ref.ID 102690]
11.Enlace a cita original Cita con resumen
Gellad WF, Thorpe CT, Steiner JF, Voils CI. The myths of medication adherence. Pharmacoepidemiol Drug Saf 2017;27:diciembre. [Ref.ID 102186]
12. Cita con resumen
Anónimo. FDA approves first digital pill. DIA Daily 2017:1. [Ref.ID 102142]
13. Cita con resumen
Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]
14. Cita con resumen
15. Cita con resumen
Aznar-Lou I, Fernández A, Gil-Gibau M, Fajó-Pascual M, Moreno-Peral P, Peñarrubia-María MT, Serrano-Blanco A, Sánchez-Niubó A, March-Pujol MA, Jové AM, Rubio-Valera M. Initial medication non-adherence: prevalence and predictive factors in a cohort of 1.6 million primary care patients. Br J Clin Pharmacol 2017;83:1328-40. [Ref.ID 101944]
16.Enlace a cita originalTiene citas relacionadas Cita con resumen
Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. Pharmacoepidemiol Drug Saf 2017;26:26 de marzo. [Ref.ID 101903]
18. Cita con resumen
Anónimo. Frailty, polypharmacy and deprescribing. Drug Ther Bull 2016;54:69-72. [Ref.ID 100403]
19.Tiene citas relacionadas
Willett WC. Mediterranean diet and fracture risk. JAMA Intern Med 2016;176:652-3. [Ref.ID 100258]
20.Tiene citas relacionadas Cita con resumen
Haring B, Crandall CJ, Wu C, LeBlanc ES, Shikanty JM, Carbone L, Orchard T, Thomas F, Wactawaski-Wende J, Li W, Cauley JA, Wassertheil-Smoller S. Dietary patterns and fractures in postmenopausal women: results from the Women's Health Initiative. JAMA Intern Med 2016;176:645-52. [Ref.ID 100257]
Seleccionar todas
 
 1 a 20 de 837 siguiente >>